Suggested remit: To appraise the clinical and cost effectiveness of roxadustat within its marketing authorisation for treating anaemia in people with chronic kidney disease.
Status Proposed
Process STA 2018
ID number 1483

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 September 2020 (10:00) Scoping workshop
14 July 2020 - 11 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of roxadustat for treating anaemia in people with chronic kidney disease ID1483. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that markets roxadustat, NICE has agreed that holding a scoping exercise at this time is not appropriate. Consequently, the scoping workshop arranged for the 17 March 20 will be cancelled. We apologise for any inconvenience this may cause. The workshop and consultation will be rescheduled to take place later in 2020. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance